Navigation Links
New study shows antibiotic may protect the heart

Virginia Commonwealth University researchers studying rapamycin, an antibiotic used to boost organ survival in transplant patients, have found that the drug may protect the heart against tissue damage following acute heart attack.

In the July issue of the Journal of Molecular and Cellular Cardiology, the official publication of the International Society for Heart Research, researchers demonstrated for the first time that pretreatment with a clinically relevant dose of rapamycin induces a protective effect against heart attack injury and reduces programmed cell death.

Researchers believe through the opening of the mitochondrial KATP channel of heart cells, rapamycin enables cells to maintain ATP levels. Mitochondria are cellular organelles critical for converting oxygen into ATP, the key fuel for cellular function.

"Rapamycin may one day be beneficial as a potential therapeutic strategy to limit cell death caused by ischemia or reperfusion injury, and possibly long-term prevention of ventricular remodeling ?the changes in size, shape and function that may occur to the left ventricle of the heart," said Rakesh C. Kukreja, Ph.D., professor of medicine and Eric Lipman Chair of Cardiology at VCU. Kukreja is lead author of the study.

Rapamycin blocks protein synthesis by inhibiting the mammalian target of rapamycin (mTOR), an essential component in the pathway of the cell cycle progression. The drug has been found to be important in transplant medicine and especially in kidney or heart transplantation. Additionally, Kukreja said that because of the antibiotic's antigrowth properties, rapamycin effectively reduces coronary restonosis, the abnormal narrowing of a blood vessel. In coronary angioplasty, stents coated with rapamycin are implanted to reduce the risk of restonosis.

"A significant clinical question will be whether or not rapamycin coated stents can be utilized in patients to favorably affect damaged heart muscle beyond the blockage causing a heart attack," said George W. Vetrovec, M.D., chair of cardiology at VCU's School of Medicine, and co-author of the study.

For the last several years, Kukreja and his colleagues have studied a class of erectile dysfunction drug known as phosphodiesterase-5 inhibitors as part of ongoing research into heart protection. The team first investigated Viagra®, generically known as sildenafil, and more recently, Levitra®, generically known as vardenafil, and found that both compounds showed protective effects in the heart during experimental heart attacks in animal models.


'"/>

Source:Virginia Commonwealth University


Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, is honored that Jay Crowley ... conference in Brussels, Belgium. , Crowley played a crucial role in the development ...
(Date:5/16/2017)... Basel, Switzerland (PRWEB) , ... May 16, 2017 ... ... for R&D, today announced its global Genedata Screener User Group Meetings, ... Genedata Screener users the opportunity to share best practices in screening data analysis ...
(Date:5/16/2017)... ... (PRWEB) May 16, 2017 , ... ... of Orthopaedic Surgeons (CAOS), long-standing development partners Invibio Biomaterial Solutions, UK, and ... surgery workshop to help expand knowledge of the implantation of Double Medical’s ...
(Date:5/15/2017)... ... May 15, 2017 , ... Continuing to ... skincare brand has today launched its first-ever cross-medium campaign, #StandFirm, with high-visibility social ... digital and social media channels, emphasizing Algenist’s stance on individuality and disruption: ...
Breaking Biology Technology: